{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:53:54Z","timestamp":1790013234223,"version":"4.0.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.jaad.2006.11.021","type":"journal-article","created":{"date-parts":[[2007,3,29]],"date-time":"2007-03-29T07:17:53Z","timestamp":1175152673000},"page":"791-802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":183,"title":["Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea"],"prefix":"10.1016","volume":"56","author":[{"given":"James Q.","family":"Del Rosso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy F.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Torok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2006.11.021_bib1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMcp042829","article-title":"Clinical practice. Rosacea","volume":"352","author":"Powell","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2006.11.021_bib2","first-page":"419","article-title":"An epidemiological study of rosacea","volume":"69","author":"Berg","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2006.11.021_bib3","first-page":"29","article-title":"Pathogenesis of rosacea","volume":"17","author":"Dahl","year":"2001","journal-title":"Adv Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/sder.2001.27553","article-title":"Rosacea: current thoughts on origin","volume":"20","author":"Bamford","year":"2001","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2006.11.021_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2004.03.030","article-title":"Rosacea: I. Etiology, pathogenesis, and subtype classification","volume":"51","author":"Crawford","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib6","first-page":"47","article-title":"Medical management of rosacea with topical agents: a thorough appraisal of available treatment options and recent advances","volume":"16","author":"Del Rosso","year":"2003","journal-title":"Cosmet Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000079886","article-title":"Rosacea: a clinicopathological approach","volume":"209","author":"Aroni","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2006.11.021_bib8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","article-title":"Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea","volume":"46","author":"Wilkin","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib9","first-page":"907","article-title":"Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea","volume":"50","author":"Wilkin","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14656566.5.1.5","article-title":"Medical treatment of rosacea with emphasis on topical therapies","volume":"5","author":"Del Rosso","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaad.2006.11.021_bib11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/archderm.1994.01690030091015","article-title":"Rosacea. Pathophysiology and treatment","volume":"130","author":"Wilkin","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib12","first-page":"499","article-title":"Rosacea: II. Therapy","volume":"51","author":"Pelle","year":"2004","journal-title":"J\u00a0Am\u00a0Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib13","first-page":"251","article-title":"Rosacea: where are we now?","volume":"3","author":"Bikowski","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib14","series-title":"Vibramycin","year":"2003"},{"key":"10.1016\/j.jaad.2006.11.021_bib15","series-title":"Oracea","year":"2006"},{"key":"10.1016\/j.jaad.2006.11.021_bib16","series-title":"Nonparametrics: statistical methods based on ranks","author":"Lehmann","year":"1975"},{"key":"10.1016\/j.jaad.2006.11.021_bib17","first-page":"351","article-title":"On the combination of independent two-sample tests of Wilcoxon","volume":"37","author":"van Elteren","year":"1960","journal-title":"Bull Int Stat Inst"},{"key":"10.1016\/j.jaad.2006.11.021_bib18","series-title":"Categorical data analysis","author":"Agresti","year":"2002"},{"key":"10.1016\/j.jaad.2006.11.021_bib19","series-title":"Analysis of ordinal categorical data","author":"Agresti","year":"1984"},{"key":"10.1016\/j.jaad.2006.11.021_bib20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA. Implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2006.11.021_bib21","series-title":"MetroGel 1%","year":"2005"},{"key":"10.1016\/j.jaad.2006.11.021_bib22","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1067\/mjd.2003.308","article-title":"Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies","volume":"48","author":"Thiboutot","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/1523-1747.ep12524458","article-title":"Oral thermal-induced flushing in erythematotelangiectatic rosacea","volume":"76","author":"Wilkin","year":"1981","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib24","first-page":"137","article-title":"Aetiology and pathogenesis of rosacea","volume":"30","author":"Sobye","year":"1950","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2006.11.021_bib25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1365-4362.1998.00275.x","article-title":"Capillaropathy and capillaroneogenesis in the pathogenesis of rosacea","volume":"37","author":"Neumann","year":"1998","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib26","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/0190-9622(91)70304-K","article-title":"A clinical and histopathologic study of granulomatous rosacea","volume":"25","author":"Helm","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib27","first-page":"497","article-title":"Demodex and rosacea, I: the prevalence and numbers of Demodex mites in rosacea","volume":"17","author":"Schmidt","year":"2004","journal-title":"Cosmet Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib28","first-page":"575","article-title":"Demodex and rosacea, II: Demodex mites and rosacea inflammation","volume":"17","author":"Schmidt","year":"2004","journal-title":"Cosmet Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaad.2004.05.034","article-title":"Demodicosis and rosacea: epidemiology and\u00a0significance in daily dermatologic practice","volume":"52","author":"Forton","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib30","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaad.2003.05.005","article-title":"Temperature regulates bacterial protein production: possible role in rosacea","volume":"50","author":"Dahl","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib31","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1365-2133.2004.05985.x","article-title":"Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis","volume":"150","author":"Dirschka","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2230.2003.01179.x","article-title":"The\u00a0role of free oxygen radicals in the aetiopathogenesis of rosacea","volume":"28","author":"Oztas","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF02850193","article-title":"Potential antioxidant mechanism of action for metronidazole: implications for rosacea management","volume":"18","author":"Miyachi","year":"2001","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaad.2006.11.021_bib34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/1523-1747.ep12285793","article-title":"Effect of antibiotics\u00a0on the generation of reactive oxygen species","volume":"86","author":"Miyachi","year":"1986","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib35","first-page":"17","article-title":"Reactive oxygen species and rosacea","volume":"74","author":"Jones","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2006.11.021_bib36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/08959374980120010501","article-title":"Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms","volume":"12","author":"Golub","year":"1998","journal-title":"Adv Dent Res"},{"key":"10.1016\/j.jaad.2006.11.021_bib37","first-page":"2","article-title":"Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils","volume":"8","author":"Jain","year":"2002","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2006.11.021_bib38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2340\/0001555572178179","article-title":"Effect of doxycycline on the generation of reactive oxygen species: a\u00a0possible mechanism of action of acne therapy with doxycycline","volume":"72","author":"Akamatsu","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2006.11.021_bib39","first-page":"13","article-title":"Ultraviolet light and rosacea","volume":"74","author":"Murphy","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2006.11.021_bib40","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1468-3083.2005.01221.x","article-title":"Could matrix metalloproteinase-9 be a link between Demodex folliculorum and rosacea?","volume":"19","author":"Bonamigo","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2006.11.021_bib41","first-page":"2506","article-title":"Tear fluid gelatinase B activity correlates with IL-1 alpha concentration and fluorescein clearance in ocular rosacea","volume":"40","author":"Alfonso","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jaad.2006.11.021_bib42","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/archderm.1994.01690060078008","article-title":"Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C","volume":"130","author":"Webster","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.11.021_bib43","doi-asserted-by":"crossref","first-page":"14014","DOI":"10.1073\/pnas.93.24.14014","article-title":"A novel mechanism of action of tetracyclines: effects on\u00a0nitric oxide synthases","volume":"93","author":"Amin","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2006.11.021_bib44","unstructured":"Fowler J. Combined effect of anti-inflammatory dose doxycycline and metronidazole topical gel 1% in the treatment of rosacea. Poster P128 presented at: 65th Annual American Academy of Dermatology Meeting; February 2-6, 2006; Washington, DC."},{"key":"10.1016\/j.jaad.2006.11.021_bib45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1540-9740.2003.03014.x","article-title":"Subantimicrobial dose doxycycline for acne and rosacea","volume":"2","author":"Bikowski","year":"2003","journal-title":"SkinMed"},{"key":"10.1016\/j.jaad.2006.11.021_bib46","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/archderm.139.4.459","article-title":"Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne","volume":"139","author":"Skidmore","year":"2003","journal-title":"Arch Dermatol"},{"issue":"Suppl 4","key":"10.1016\/j.jaad.2006.11.021_bib47","first-page":"6","article-title":"The anti-inflammatory effects of tetracyclines","volume":"75","author":"Weinberg","year":"2005","journal-title":"Cutis"},{"issue":"Suppl 4","key":"10.1016\/j.jaad.2006.11.021_bib48","first-page":"19","article-title":"Subantimicrobial dose doxycycline: a unique treatment for rosacea","volume":"75","author":"Berman","year":"2005","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2006.11.021_bib49","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2006.11.021_bib50","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaad.2006.11.021_bib51","unstructured":"Walker C, Webster GF. A multicenter, double-blind, randomized trial to evaluate the long-term safety of anti-inflammatory dose doxycycline. Poster presented at: Fall Clinical Dermatology Conference, The Foundation for Research and Education in Dermatology; October 6-9, 2006; Las Vegas, Nev."}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206040436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206040436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:06:54Z","timestamp":1759270014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962206040436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0190962206040436"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2006.11.021","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2006.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}